From a biomarker perspective, MRD testing in ovarian cancer can be integrated with established markers like CA-125, allowing ctDNA to detect recurrence earlier or in cases where CA-125 is non-informative, which gives gynecologic MRD a distinctive multimodal character. This evidence concerns the gene MUC16 and ovarian carcinoma.